vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving Average – What’s Next?

vTv Therapeutics Inc. (NASDAQ:VTVT) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $36.23 and traded as high as $37.99. vTv Therapeutics shares last traded at $35.31, with a volume of 16,208 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on VTVT shares. BTIG Research restated a “buy” rating and issued a $49.00 price target (up previously from $40.00) on shares of vTv Therapeutics in a research report on Tuesday, January 27th. HC Wainwright reissued a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Wall Street Zen raised vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. Finally, TD Cowen initiated coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.25.

vTv Therapeutics Stock Performance

The firm has a market capitalization of $139.12 million, a price-to-earnings ratio of -10.64 and a beta of 0.50. The firm has a fifty day moving average price of $36.23 and a 200 day moving average price of $27.06.

Institutional Investors Weigh In On vTv Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics in the 4th quarter valued at about $221,000. 683 Capital Management LLC acquired a new position in vTv Therapeutics during the fourth quarter worth about $731,000. Geode Capital Management LLC increased its holdings in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its holdings in vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares in the last quarter. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.